Fluorine F 18 Fluorthanatrace PET/CT Imaging for Breast Cancer
Trial Summary
What is the purpose of this trial?
This phase II trial tests whether \[18F\]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery. \[18F\]FluorThanatrace is a new radioactive tracer, which is a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, \[18F\]FluorThanatrace. Because some cancers take up \[18F\]FluorThanatrace it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. \[18F\]FluorThanatrace by PET/CT may help detect the activity of a certain enzyme in the body that may be related to cancer growth in patients with breast cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are undergoing any current or prior therapy for breast cancer, you may not be eligible to participate.
What data supports the effectiveness of the treatment Fluorine F 18 Fluorthanatrace for breast cancer?
Is Fluorine F 18 Fluorthanatrace safe for use in humans?
How is Fluorine F 18 Fluorthanatrace PET/CT Imaging unique for breast cancer treatment?
Fluorine F 18 Fluorthanatrace is unique because it is a PET radiotracer specifically designed to image PARP-1, a protein involved in DNA repair, which is a target for certain breast cancer drugs. This imaging technique helps visualize the expression levels of PARP-1 in breast cancer, providing a novel way to assess the presence and activity of this protein in tumors.16101112
Research Team
Lilie L Lilie
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for adults over 18 with breast cancer who are candidates for primary breast surgery and have a tumor of at least 1.0 cm visible on imaging. It's not for those pregnant, breastfeeding, previously treated for their breast cancer, unable to tolerate imaging procedures, or with conditions that may compromise safety or participation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Participants receive [18F]FTT intravenously and undergo PET/CT scan over 20-30 minutes
Optional Follow-up Imaging
Participants may undergo an optional PET/CT scan 1 week after the baseline scan
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- Fluorine F 18 Fluorthanatrace
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Trevarx Biomedical, Inc
Collaborator